Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2025Human Vaccines & ImmunotherapeuticsOpen Access

Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

MJMingwei JiangShenzhen UniversityJZJinrong ZhaoXinjiang Medical UniversityJYJinguo YuanXijing Hospital

Discussion

Loading...

Member takes

Implication

Research outlines the effectiveness of CAR T cell therapy on autoimmune diseases, suggesting new therapeutic pathways and safety profiles.

Key Points

  • Chimeric antigen receptor (CAR) T cell therapy shows long-term remission potential without drugs in autoimmune diseases.
  • Early clinical trials demonstrate promising efficacy and safety of CAR natural killer cell therapy.
  • The transition of chimeric autoantigen receptor T cell therapy from research to clinical trials marks a significant advancement.
  • Continued research aims to enhance the efficiency and safety of CAR-based immunotherapy for broader autoimmune disease applications.

Cite This Study

Jiang et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d00aahttps://doi.org/10.1080/21645515.2025.2538350
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis2024 · 189 citations
  2. 2A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow2015 · 241 citations
  3. 3Immunologic Characterization of CD7-Deficient Mice1998 · 70 citations
  4. 4RNA-Guided Human Genome Engineering via Cas92013 · 9,559 citations
  5. 5Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure2025 · 43 citations